TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 5, 2013, details the results of the annual meeting of stockholders held by TG Therapeutics, Inc. on June 5, 2013. The meeting took place at the offices of Alston & Bird LLP in New York, New York.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Stockholders representing 21,841,709 shares (82.97% of the 26,322,671 shares entitled to vote) were present in person or by proxy. All four management proposals were approved:
- Proposal 1 (Election of Directors): Six directors were elected to serve until the 2014 annual meeting: Michael S. Weiss, Neil Herskowitz, Laurence N. Charney, William J. Kennedy, Mark Schoenebaum, MD, and Yann Echelard. Voting was overwhelmingly in favor, with minimal votes withheld.
- Proposal 2 (Ratification of Auditors): CohnReznick LLP was approved as the independent registered public accountant for the 2013 fiscal year.
- Proposal 3 (Executive Compensation): The advisory vote on the compensation of named executive officers was approved.
- Proposal 4 (Frequency of Say-on-Pay): Shareholders voted to hold an advisory vote on executive compensation every three years.
Guidance, Outlook, and Risks
The filing does not provide management commentary on business outlook, financial guidance, risks, contingencies, or unusual items. It is a procedural report regarding the annual meeting.
Key Facts for Investor Verification
- Verify the tenure of the newly elected board members, which extends until the 2014 annual meeting.
- Confirm the appointment of CohnReznick LLP as the independent auditor for the 2013 fiscal year.
- Note the shareholder preference for a three-year cycle for future advisory votes on executive compensation.
- Review the definitive proxy statement dated April 24, 2013, for detailed descriptions of the proposals and director biographies.